Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease

Research output: Contribution to journalReview articlepeer-review

54 Scopus citations


Parkinson's disease (PD) is caused by the progressive degeneration of dopaminergic neurons in the substantia nigra. Although the etiology for most PD remains elusive, the identification of specific genetic defects in familial cases of PD and the signaling pathways governed by these genes has provided tremendous insight into PD pathogenesis. Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are frequently found in familial and sporadic PD. Although current knowledge regarding the regulatory mechanisms of LRRK2 activation is limited, it is becoming increasingly evident that aberrant kinase activity of the pathologic mutants of LRRK2 is associated with neurodegeneration, suggesting that the kinase activity of LRRK2 is a potential therapeutic target. In addition, LRRK2 inhibitors might provide valuable tools to understand the pathophysiological and physiological roles of LRRK2 as well as the etiology of PD. We discuss here the potential and feasibility of targeting LRRK2 as a therapeutic strategy for PD.

Original languageEnglish (US)
Pages (from-to)365-373
Number of pages9
JournalTrends in Pharmacological Sciences
Issue number7
StatePublished - Jul 2012

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology


Dive into the research topics of 'Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease'. Together they form a unique fingerprint.

Cite this